flere maligniteter, primært i lunger eller hoved og hals, hos infliximab- behandlede patienter end hos kontrol- patienter.
with moderate to severe chronic obstructive pulmonary disease (COPD), more malignancies, mostly in the lung or head and neck, were reported in infliximab-treated patients compared with control patients.